Home > Insider Trading > Filing (0000899243-17-024682)

Filing Details

Accession Number:: 0000899243-17-024682
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-10-25 16:05:26
Reporting Period:: 2017-10-23

Accepted Time:: 2017-10-25 16:05:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631650	Aimmune Therapeutics Inc.	AIMT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1488637	T. Douglas Sheehy	Aimmune Therapeutics, Inc. 8000 Marina Boulevard, Suite 300 Brisbane CA 94005-1884	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, $0.0001 Par Value	Acquisiton	2017-10-23	34,300	$12.95	34,300	No	4	M	Direct
Common Stock, $0.0001 Par Value	Disposition	2017-10-23	22,964	$33.25	11,336	No	4	S	Direct
Common Stock, $0.0001 Par Value	Disposition	2017-10-23	5,003	$34.13	6,333	No	4	S	Direct
Common Stock, $0.0001 Par Value	Disposition	2017-10-23	6,333	$35.34	0	No	4	S	Direct
Common Stock, $0.0001 Par Value	Acquisiton	2017-10-23	13,125	$19.63	13,125	No	4	M	Direct
Common Stock, $0.0001 Par Value	Disposition	2017-10-23	7,500	$35.63	5,625	No	4	S	Direct
Common Stock, $0.0001 Par Value	Disposition	2017-10-23	5,625	$37.00	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2017-10-23	34,300	$0.00	34,300	$12.95
Common Stock	Stock Option (right to buy)	Disposition	2017-10-23	13,125	$0.00	13,125	$19.63

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
75,700		2026-04-29	No	4	M	Direct
76,875		2027-02-24	No	4	M	Direct

Footnotes

This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
The transaction was executed in multiple trades in prices ranging from $32.79 to $33.78, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The transaction was executed in multiple trades in prices ranging from $33.80 to $34.79, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The transaction was executed in multiple trades in prices ranging from $34.80 to $35.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The transaction was executed in multiple trades in prices ranging from $35.55 to $36.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 4, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from February 24, 2017, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.